Avian infectious bronchitis virus enters cells via the endocytic pathway.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Drug repurposing approach to combating coronavirus: Potential drugs and drug targets.Medicinal research reviews · 2021
   Review
2. Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine.International journal of antimicrobial agents · 2021
   Article
3. Repurposing host-based therapeutics to control coronavirus and influenza virus.Drug discovery today · 2019
   Review
4. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture.Antimicrobial agents and chemotherapy · 2014
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

5 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as